IDSA’s new policy paper, “Combating Antimicrobial Resistance: Policy Recommendations to Save Lives,” can be accessed here . In its policy paper, IDSA makes the following recommendations:
• Creating incentives and removing economic and regulatory disincentives for antibiotic research and development so companies find developing new antibiotics a viable business endeavor.
• Recalibrating and better communicating the FDA’s requirements for new antibiotic approvals.
• Funding antibiotic R&D efforts under the Department of Health and Human Services’ Biomedical Advanced Research and Development Authority and proposed independent strategic investment firm.
• Supporting R&D for rapid diagnostic tests to identify the cause of infections more quickly.
• Designating a leader within HHS to facilitate coordination of federal efforts and better utilize outside experts.
• Promoting the judicious use of available antibiotics through better stewardship programs and infection control practices.
• Creating an Antimicrobial Innovation and Conservation Fee to help pay for drug development and stewardship.
• Strengthening public health measures and research that lead to new interventions.
• Establishing non-profit public-private partnerships to invest in bringing new antibiotics to market.
Read the news release about IDSA’s recommendations to combat antibiotic-resistant “super bugs.”
Read other coverage about antibiotic-resistant “super bugs”:
– Dr. Edo McGowan Responds to Study Indicating MRSA Infection May Be Seasonal
– Environmental Cleaning and Disinfection: What Infection Preventionists Need to Know
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.